Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia
CLOZAPINE probably leads to lower global impression: 1. Not clinically improved ‐ short term compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
3 findings from 1 review
RR 0.71 [0.64, 0.79]
4 studies · 370 participants
Moderate
RR 0.83 [0.76, 0.91]
2 studies · 648 participants
Moderate
RR 0.72 [0.66, 0.79]
14 studies · 1119 participants
Moderate
Adverse effects 1. Blood problems · patients with schizophrenia
CLOZAPINE showed no clear difference in adverse effects 1. Blood problems compared with TYPICAL ANTIPSYCHOTICS; GRADE not reported.
1 finding from 1 review
Adverse effects 4. Salivation ‐ too much · patients with schizophrenia
CLOZAPINE probably leads to higher adverse effects 4. Salivation ‐ too much compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
2 findings from 1 review
Weight gain · patients with schizophrenia
CLOZAPINE probably leads to higher adverse effects 5. Weight gain compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
2 findings from 1 review
Unable to work · patients with schizophrenia
CLOZAPINE showed no clear difference in unable to work compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).
1 finding from 1 review
Adverse effects: 1. Blood problems ‐ decreased white cell count · patients with schizophrenia
CLOZAPINE probably leads to higher adverse effects: 1. Blood problems ‐ decreased white cell count compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).
1 finding from 1 review
Clinically important change in positive symptoms · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Clinically important change in negative symptoms · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Catatonia: clinically important change in catatonia symptoms (improved at least 50% on the VAS) · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Clinically important adverse drug‐induced movement disorder effects on the central nervous system (EPS, NMS, MC) · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Clinically important adverse effects other than central nervous system or EPS · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Mental state · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: any ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effects: use of antiparkinsonism drugs · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether switch to another antipsychotic changes adverse effects: use of antiparkinsonism drugs compared with antipsychotic cessation (very low certainty).
1 finding from 1 review
Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether switch to another antipsychotic changes acceptability of the treatment: leaving the study early compared with antipsychotic cessation (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
General mental state: Deterioration · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse events: extrapyramidal symptoms (need of antiparkinsonism drugs) · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review